New antibody targets Hard-to-Treat cancers in early trial

NCT ID NCT07292168

First seen Jan 05, 2026 · Last updated May 04, 2026 · Updated 21 times

Summary

This study tests a new antibody drug, OM-RCA-01, in people with advanced cancers that have a specific protein called FGFR1. The goal is to see if the drug is safe and can slow tumor growth. About 58 adults with kidney, lung, prostate, breast, or head & neck cancer will receive the drug by IV every two weeks. This is an early-phase trial, so the main focus is safety and finding the right dose.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD & NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • A.I. Kryzhanovsky Krasnoyarsk Regional Cancer Center

    RECRUITING

    Krasnoyarsk, Russia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hadassah Medical

    RECRUITING

    Moscow, Russia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • I.P. Pavlov First Saint Petersburg State Medical University

    RECRUITING

    Saint Petersburg, Russia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Republican Clinical Oncology Dispensary

    RECRUITING

    Ufa, Russia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Republican Dispensary of Tatarstan

    ACTIVE_NOT_RECRUITING

    Kazan', Russia

Conditions

Explore the condition pages connected to this study.